(Q43492164)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

24 November 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial (English)

1 reference

24 November 2017

7

Issei Komuro

1 reference

24 November 2017

6

Yoichi Kuwabara

1 reference

24 November 2017

3

Satoshi Shindo

1 reference

24 November 2017

1

Hiroya Narumi

1 reference

24 November 2017

4

Miwa Fujita

1 reference

24 November 2017

Hiroyuki Takano

2

1 reference

24 November 2017

Hiroshi Mizuma

series ordinal

5

1 reference

24 November 2017

Valsartan Amlodipine Randomized Trial Investigators

series ordinal

8

1 reference

24 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20927112

28 July 2024

publication date

7 October 2010

1 reference

full work available at URL

24 November 2017

https://www.nature.com/articles/hr2010186.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20927112

http://www.jstage.jst.go.jp/article/hypres/34/1/34_62/_article

28 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20927112

http://www.nature.com/articles/hr2010186.pdf

28 July 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/HR.2010.186

http://www.nature.com/articles/hr2010186

28 July 2024

1 reference

https://api.crossref.org/works/10.1038/HR.2010.186

28 July 2024

published in

Hypertension Research

1 reference

24 November 2017

volume

34

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

62-69

1 reference

Retraction: Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial

24 November 2017

is retracted by

0 references

cites work

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Determinants of survival and left ventricular performance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Glomerular permselectivity in early stages of overt diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Glomerular hypertension as one cause of albuminuria in type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Microalbuminuria and Peripheral Arterial Disease Are Independent Predictors of Cardiovascular and All-Cause Mortality, Especially Among Hypertensive Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Cardiovascular and metabolic benefits of ACE inhibition: moving beyond blood pressure reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

Reliability of echocardiographic assessment of left ventricular structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

7 January 2021

Left Ventricular Mass and Risk of Stroke in an Elderly Cohort

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

7 January 2021

Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

7 January 2021

Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

7 January 2021

Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

7 January 2021

Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

7 January 2021

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

7 January 2021

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

7 January 2021

Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.186

7 January 2021

Angiotensin receptor blockers: baseline therapy in hypertension?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1038/HR.2010.186

Identifiers

DOI

10.1038/HR.2010.186

1 reference

24 November 2017

1 reference